Generic name: insulin glargine 100[iU] in 1mL
Dosage form: injection, solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Important Administration Instructions
- Administer LANTUS subcutaneously once daily at any time of day but at the same time every day.
- Prior to initiation of LANTUS, train patients on proper use and injection technique.
- Patient should follow the Instructions for Use to correctly administer LANTUS.
- Administer LANTUS subcutaneously into the abdominal area, thigh, or deltoid, and rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)].
- Visually inspect LANTUS vials and SoloStar prefilled pens for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.
- Refrigerate unused (unopened) LANTUS vials and SoloStar® prefilled pens.
- Do not administer intravenously or via an insulin pump.
- Do not dilute or mix LANTUS with any other insulin or solution.
- The SoloStar prefilled pen is for single patient use only [see Warning and Precautions (5.1)].
General Dosing Instructions
- Individualize and adjust the dosage of LANTUS based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function. Dosage adjustments should only be made under medical supervision with appropriate glucose monitoring [see Warnings and Precautions (5.2)].
Initiation of LANTUS Therapy
Type 1 Diabetes:
- In patients with type 1 diabetes, LANTUS must be used concomitantly with short-acting insulin.The recommended starting dose of LANTUS in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.
Type 2 Diabetes:
- The recommended starting dose of LANTUS in patients with type 2 diabetes who are not currently treated with insulin is 0.2 units/kg or up to 10 units once daily. One may need to adjust the amount and timing of short- or rapid-acting insulins and dosages of any oral anti-diabetic drugs.
Changing to LANTUS from Other Insulin Therapies
- If changing patients from once daily TOUJEO (insulin glargine) 300 Units/mL to once daily LANTUS, the recommended initial LANTUS dose is 80% of the TOUJEO dose that is being discontinued. This dose reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
- If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with LANTUS, a change in the dose of the basal insulin may be required and the amount and timing of the shorter-acting insulins and doses of any oral anti-diabetic drugs may be needed to be adjusted.
- If changing patients from once-daily NPH insulin to once-daily LANTUS, the recommended initial LANTUS dose is the same as the dose of NPH that is being discontinued.
- If changing patients from twice-daily NPH insulin to once-daily LANTUS, the recommended initial LANTUS dosage is 80% of the total NPH dose that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia [see Warnings and Precautions (5.3)].
More about Lantus (insulin glargine)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 23 Reviews – Add your own review/rating
- Drug class: insulin